University of Cape Town

Era Biotech, S.a.

Mitsubishi Tanabe Pharma Corporation

Medicago Inc.

Zera Intein Protein Solutions, S.l.

Inga Isabel Hitzeroth

Edward Peter Rybicki

Ann Elizabeth Meyers

Marc-Andre D'Aoust

Pierre-Olivier Lavoie

Nathalie Landry

Pablo Marzábal Luna

Naomi Asahara

Masaaki Arai

Peter Öhlschläger

François Devesa

Edward P Rybicki

David Levi Rutendo Mutepfa

Peter ÖHLSCHLÄGER

Edwar Peter Rybicki

The present invention relates to a fusion protein consisting of a scFv linked to a horseradish peroxidase enzyme or to an alkaline phosphatase enzyme by a peptide linker. The fusion protein also includes a histidine tag and optionally an endoplasmic reticulum retention signal. The invention also includes nucleic acids encoding the fusion protein, expression vectors containing the nucleic acids, plant cells transformed with the expression vectors and methods of producing the fusion proteins of the invention.

Production of a horseradish peroxidase-igg fusion protein

The present invention relates to a method of producing HPV pseudovirions in plant cells, the plant produced pseudovirions per se, a neutralization assay using the plant produced pseudovirions and pharmaceutical compositions comprising the plant produced pseudovirions.

Plant produced human papillomavirus pseudovirion

This invention relates to a chimaeric human papillomavirus (HPV) virus like particle (VLP) having a diameter of about 30 nm. The invention further relates to methods of treatment and/or prophylaxis of HPV infection and/or cervical cancer by administration of the chimaeric HPV VLP of the invention to a subject.

HPV chimaeric particle

An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence.

Recombinant protein bodies as immunogen-specific adjuvants

Growing community of inventors

Cape Town, South Africa

Inga Isabel Hitzeroth